Jennifer W Witcher

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
    Jennifer W Witcher
    Eli Lilly and Company, Lilly Research Laboratories, Corporate Center, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 13:53-63. 2003
  2. ncbi request reprint Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome
    John Michael Sauer
    Department of Clinical Pharmacology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 308:410-8. 2004
  3. ncbi request reprint Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism
    John Michael Sauer
    Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 31:98-107. 2003
  4. ncbi request reprint Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
    Donna J Belle
    Department of Clinical Pharmacology, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 42:1219-27. 2002
  5. ncbi request reprint CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Eur Neuropsychopharmacol 18:79-86. 2008
  6. ncbi request reprint Clinical pharmacokinetics of atomoxetine
    John Michael Sauer
    Elan Pharmaceuticals, Inc, South San Francisco, California, USA
    Clin Pharmacokinet 44:571-90. 2005

Detail Information

Publications6

  1. ncbi request reprint Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
    Jennifer W Witcher
    Eli Lilly and Company, Lilly Research Laboratories, Corporate Center, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 13:53-63. 2003
    ..This study was conducted, in part, to evaluate the single-dose and steady-state pharmacokinetics of atomoxetine in pediatric patients...
  2. ncbi request reprint Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome
    John Michael Sauer
    Department of Clinical Pharmacology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 308:410-8. 2004
    ....
  3. ncbi request reprint Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism
    John Michael Sauer
    Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 31:98-107. 2003
    ..Although differences were observed in the excretion and relative amounts of metabolites formed, the primary difference observed between EM and PM subjects was the rate at which atomoxetine was biotransformed to 4-hydroxyatomoxetine...
  4. ncbi request reprint Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
    Donna J Belle
    Department of Clinical Pharmacology, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 42:1219-27. 2002
    ..It was concluded that inhibition of CYP2D6 by paroxetine markedly affected atomoxetine disposition, resulting in pharmacokinetics similar to poor metabolizers of CYP2D6 substrates...
  5. ncbi request reprint CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Eur Neuropsychopharmacol 18:79-86. 2008
    ..Results suggest genotyping is unnecessary during routine clinical management, because investigators were able to dose atomoxetine to comparable efficacy and safety levels in EMs and PMs without knowledge of genotype metabolizer status...
  6. ncbi request reprint Clinical pharmacokinetics of atomoxetine
    John Michael Sauer
    Elan Pharmaceuticals, Inc, South San Francisco, California, USA
    Clin Pharmacokinet 44:571-90. 2005
    ..In extensive metabolisers, potent and selective CYP2D6 inhibitors reduce atomoxetine clearance; however, administration of CYP inhibitors to poor metabolisers has no effect on the steady-state plasma concentrations of atomoxetine...